General Information of Drug (ID: DM4VCJI)

Drug Name
Rovelizumab Drug Info
Synonyms LeukArrest; Hu23F2G; Monoclonal antibody (MS), ICOS; 23F2G, ICOS
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular disease 8B2Z Terminated [1]
Cross-matching ID
TTD Drug ID
DM4VCJI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PRX003 DM5KI6X Psoriasis vulgaris EA90 Phase 1 [3]
ABX-MA1 DMZYVPB Melanoma 2C30 Discontinued in Phase 1 [4]
ABS-205 DMALPDW Neurodegenerative disorder 8A20-8A23 Terminated [5]
CY-1748 DM0X147 Deep vein thrombosis BD71 Terminated [6]
ICM-3 DMDBICR Graft-versus-host disease 4B24 Terminated [7]
GM-7050 DMEVIP9 Inflammation 1A00-CA43.1 Terminated [8]
NPC-17923 DMD01GK Rheumatoid arthritis FA20 Terminated [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cell adhesion molecule (CADM) TTD26RC NOUNIPROTAC Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006028)
2 Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
5 Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21).
6 US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation.
7 Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60.
8 US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
9 Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72.